RxDoctor Payments Data

Patrick Hourani, MD

Interventional Cardiology · Miami, FLNPI 1386975175

Payments from drug & device makers

$14,514in general payments, 2019–2025

Across 474 payments — averaging $30.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Boston Scientific$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$798
  • AstraZeneca$778
  • Boehringer Ingelheim$777
  • Pfizer$717
  • plus $6K from 36 others

What the payments were for

  • Food & beverage$14,37199%
  • Education$1431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,514 in reported general payments places this provider in the 60th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$315,436
Medicare patients
647
Services billed
3,207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban447$556,332
EntrestoSacubitril/Valsartan301$429,111
FarxigaDapagliflozin Propanediol258$319,379
XareltoRivaroxaban128$140,279
JardianceEmpagliflozin133$133,017
BrilintaTicagrelor105$90,891
VascepaIcosapent Ethyl92$64,339
Repatha SureclickEvolocumab54$52,759
MultaqDronedarone Hcl15$25,785
VerquvoVericiguat16$23,260
Repatha SyringeEvolocumab11$13,038
DapagliflozinDapagliflozin Propanediol19$9,398
Atorvastatin Calcium788$6,486
Ezetimibe230$4,455
NexlizetBempedoic Acid/Ezetimibe11$4,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$717$556,332447 claims
NovartisEntresto$328$429,111301 claims
AstraZenecaFarxiga, Brilinta$778$410,269363 claims
Johnson & JohnsonXarelto$461$140,279128 claims
Boehringer IngelheimJardiance$777$133,017133 claims
Sanofi-aventis U.S. LLCMultaq$46$25,78515 claims
MerckVerquvo$503$23,26016 claims
Esperion Therapeutics, Inc.Nexlizet$58$4,40811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →